Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B brings in $12.5mm for Molecular Biometrics

Executive Summary

Molecular Biometrics (diagnostics for cardiovascular, gynecological, and neurological use) has raised $12.5mm through its Series B venture round. New backer Atlas Venture led and was joined by current shareholders Safeguard Scientifics and Oxford Bioscience Partners. Funds will be used to complete an ongoing FDA clinical study of and launch its ViaMetrics-E, a noninvasive procedure to help identify viable embryos and potentially improve the success rate of in vitro fertilization.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies